Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2024年度“提质增效重回报”专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "Half-Year Assessment Report" for a specific 2024 action plan by the company. It contains detailed financial data for the first half of 2024, including revenue, net profit, R&D expenses, dividend distribution, and operational updates. The report discusses the implementation and evaluation of a strategic action plan, financial performance, dividend payments, investor relations, and governance activities during the half-year period. The presence of actual financial figures and substantive analysis for a period shorter than a full fiscal year indicates this is a comprehensive interim or quarterly report rather than a brief announcement or a regulatory filing. The document length is 2101 characters, which is relatively short but contains detailed financial data and analysis, meeting the criteria for an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
江苏浩欧博生物医药股份有限公司关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the signing certified public accountant for the company's 2024 financial audit. It references the appointment and replacement of auditors but does not contain any financial statements or audit reports themselves. The document is relatively short (1187 characters) and serves to inform about a personnel change related to the audit process. This fits the category of Audit Report / Information (AR), which includes standalone audit-related announcements excluding full annual reports. It is not a full audit report but an audit-related information announcement, so AR is appropriate with high confidence. FY 2024
2024-08-26 Chinese
江苏浩欧博生物医药股份有限公司关于2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company during the half-year period of 2024. It includes specifics on the amount raised, timing, usage, balance, and compliance with regulatory requirements. The document references regulatory guidelines related to fundraising management and provides a comprehensive breakdown of fund usage, investment projects, and cash management activities. The length of the document (5132 characters) and the detailed financial data indicate it is a substantive report rather than a brief announcement. The content aligns with a specialized report on fundraising usage rather than a general financial report or earnings release. Therefore, the document fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage.
2024-08-26 Chinese
江苏浩欧博生物医药股份有限公司2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The document length is 2949 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. It is not merely an announcement or a certification but includes key financial metrics and shareholder data typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
江苏浩欧博生物医药股份有限公司第三届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the approval of the company's 2024 semi-annual report and a special report on the use of raised funds. It references the 2024 semi-annual report and the special report but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (1260 characters) and directs readers to the Shanghai Stock Exchange website for the full reports. This fits the pattern of an announcement of meeting resolutions and approvals rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement of supervisory board resolutions and references reports without including them in full.
2024-08-26 Chinese
江苏浩欧博生物医药股份有限公司2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, earnings per share, and management discussion and analysis. It also contains sections on company overview, risk factors, governance, and environmental and social responsibility. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.